$ATXI GREATER GAINS AHEAD ON PHASE 3 SUCCESS

ATXI TRADED ON HIGH VOLUME AND A INITIAL 30% PRICE SPIKE ON MONDAY BUT SOLD OFF AS THE MARKET CONDITIONS DETERIORATED THROUGHOUT THE DAY. KEEP ON STRONG WATCH AS A MUCH GREATER MOVE IS EXPECTED ON SUCH STRONG RESULTS.
COMPANY COMMENTS
“The strong safety and efficacy results from this second Phase 3 trial are consistent with those from the first Phase 3 trial in bunionectomy surgery and demonstrated the utility of IV tramadol in post-surgical pain management regardless of the surgery type,” said CEO Lucy Lu in a press release. “This study is a significant milestone for Avenue because it brings us one step closer to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), currently planned for year-end 2019."

AVERAGE ANALYSTS PRICE TARGET $11.67
AVERAGE ANALYSTS RECOMMENDATION BUY

COMPANY PROFILE
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.